- Human（2）
No data
- Fc Tag（1）
- His Tag（1）
No data
- HEK293（2）
No data
- Unconjugated（2）
No data
- RUO（2）
No data
- Yes（1）
- No（1）
No data
- 100ug/$360.00
- 1mg (500ug X 2)/$2380.00
No data
- 100ug/$360.00
- 1mg/$2380.00
No data
| Molecule | Cat. No. | Product Name | Species | Host | Structure | Purity | Activity | Size&Price | Add to Cart |
|---|---|---|---|---|---|---|---|---|---|
| TRAC | Human TRAC Protein, Fc Tag |  Human | HEK293 |  | SDS-PAGE | $360.00 100ug |   | ||
| TRAC | Human TRAC Protein, His Tag, low endotoxin | Human | HEK293 |  | SDS-PAGE | $360.00 100ug | |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| MT-2765 | MT-2765 | Phase 3 Clinical | Mitsubishi Tanabe Pharma Corp | Hypertension | Details |
| SP-20104 (Sarfez Pharmaceuticals) | SP-20104 | Phase 2 Clinical | 1 A Pharma Gmbh | Glomerulosclerosis, Focal Segmental | Details |
| Imarikiren hydrochloride | TAK-272; SCO-272 | Phase 2 Clinical | Takeda Pharmaceutical Co Ltd | Kidney Diseases; Hypertension; Diabetic Nephropathies; Hepatic Insufficiency | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Aliskiren Hemifumarate/Amlodipine Besilate/Hydrochlorothiazide | Approved | Novartis Pharma Ag | Rasitrio, Amturnide | United States | Hypertension | null | 2010-12-21 | Hypertension; Essential Hypertension | Details | |
| Aliskiren Hemifumarate | SPP-100; SPP-100A; SPP-100B; CGP-60536; CGP-60536B | Approved | Novartis Pharma Ag | Enviage, Rasilez, Riprazo, Sprimeo, Tekturna, 锐思力 | United States | Hypertension | Noden Pharma Dac | 2007-03-05 | Myocardial Ischemia; Heart Failure; Myocardial Infarction; Diabetes Mellitus, Type 2; Glomerulonephritis, IGA; Coronary Artery Disease; Hypertension; Hypertrophy, Left Ventricular; Diabetic macular oedema; Cardiovascular Diseases; Diabetic Nephropathies; Essential Hypertension; Overweight; Diabetes Mellitus; Kidney Failure, Chronic | Details |
| Aliskiren | Approved | Mainland China | Essential Hypertension | Novartis Pharma Ag | 2010-03-26 | Essential Hypertension | Details |
